Information Provided By: 
Fly News Breaks for June 6, 2018
EXAS
Jun 6, 2018 | 07:51 EDT
Canaccord analyst Mark Massaro said Exact Sciences' update on its liver cancer test candidate is a positive. The analyst noted the company reported strong accuracy for a blood-based liver cancer test to the tune of 95% sensitivity and 93% specificity, which at face-value is superior to Cologuard. Massaro reiterated his Buy rating and raised his price target to $70 from $68 on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
